Oral Diabetes Drug Trial Results Published
A new academic paper highlights potential for an oral treatment to combat diabetic retinopathy progression.
Updated on Sept. 23, 2026 in Diabetes
Live Poll
Would you prefer oral medication over eye injections for treating chronic retinal conditions?
Science Translational Medicine has published an academic paper analyzing pre-clinical and Phase 1b clinical data for danegaptide. The oral small molecule drug is designed to stabilize retinal vasculature in patients with diabetic retinopathy.
Why it matters
Current standard-of-care treatments for non-proliferative diabetic retinopathy (NPDR) often require invasive intravitreal injections. This oral alternative aims to improve patient access and adherence to treatment for the condition.
Approximately 130 million people worldwide suffer from diabetic retinopathy, a condition currently managed by invasive injections. Danegaptide works by protecting the inner blood-retina barrier and dampening VEGF-associated activity.
The players
Breye Therapeutics
A pharmaceutical company based in Copenhagen, Denmark, that is focused on developing new treatments for retinal diseases.
Science Translational Medicine
A peer-reviewed journal that publishes research on the conversion of basic science discoveries into medical applications.
The details
Danegaptide functions as an oral small molecule that stabilizes retinal vessels to prevent capillary breakdown. Researchers developed the drug to provide a less burdensome way to protect vision compared to existing invasive procedures.
Timeline
September 23, 2026: The academic paper was published in Science Translational Medicine.
2027: Breye Therapeutics plans to start a Phase II clinical trial for the drug.
The Big Picture
This study marks a departure from established injection-based protocols by proposing a novel oral pill-based therapeutic path.
This development could eventually replace invasive eye injections with a simpler oral pill regimen for early-stage diabetic retinopathy. Such a change would significantly reduce the physical burden and healthcare access barriers currently faced by patients.
The takeaway
The transition from invasive injections to oral medications represents a significant milestone in chronic disease management. Patients and providers should monitor future clinical trial updates to see if this candidate maintains its safety and efficacy profile.
What happens next
Breye Therapeutics plans to initiate a Phase II clinical trial for danegaptide in 2027 to further evaluate the drug's performance in humans.
Further reading
Learn more about the latest research and management techniques for Diabetes.
More information
For more information on the company's research pipeline, visit the Breye Therapeutics corporate website.
Live Poll
Would you prefer oral medication over eye injections for treating chronic retinal conditions?
